Open Nav

How Real-World Evidence Can Improve Clinical Trial Productivity

  • Cartier Esham, Biotechnology Innovation Organization (BIO),
  • Ken Carson, Flatiron Health,
  • Gracie Lieberman , Genentech,
  • Jeremy Rassen, Aetion ,
  • Komathi Stem, monARC Bionetworks

As a greater percentage of health care records are digitized, plus with the emergence of patient-provided data sets via wearables and other devices, therapy developers have much greater ability to distill insights from existing data rather than solely relying upon “started from scratch” clinical trials to learn about a disease. Companies are combining new analytical techniques with careful human screening of real world data sources such as electronic health records, insurance billing records, and patients’ mobile devices to develop real-world evidence regarding which patient populations might respond best to a new treatment under development and which diagnostic markers might streamline clinical trial recruitment. In the light of the FDA’s new guidance on real-world evidence this panel will explain how traditional approaches to clinical trial design may be enhanced to save time and money, while improving productivity and outcomes for patients.

  • Date:Thursday, October 18
  • Time:1:45 PM - 2:40 PM
  • Session Type:Educational Session
Cartier Esham
Biotechnology Innovation Organization (BIO)
Ken Carson
Flatiron Health
Gracie Lieberman
Jeremy Rassen
Komathi Stem
monARC Bionetworks